1. “Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies”
by Brian A. Baldo
Antibodies 2022, 11(1), 17; https://doi.org/10.3390/antib11010017
Available online: https://www.mdpi.com/2073-4468/11/1/17

2. “Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS”
by Emmanuel J. Favaloro, Leonardo Pasalic and Giuseppe Lippi
Antibodies 2022, 11(1), 7; https://doi.org/10.3390/antib11010007
Available online: https://www.mdpi.com/2073-4468/11/1/7

3. “Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library”
by Ivette Mendoza-Salazar, Keyla M. Gómez-Castellano, Edith González-González, Ramsés Gamboa-Suasnavart, Stefany D. Rodríguez-Luna, Giovanni Santiago-Casas, María I. Cortés-Paniagua, Sonia M. Pérez-Tapia and Juan C. Almagro
Antibodies 2022, 11(1), 13; https://doi.org/10.3390/antib11010013
Available online: https://www.mdpi.com/2073-4468/11/1/13

4. “Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C—Can We Match the Puzzle?”
by Snezhina Lazova, Yulia Dimitrova, Diana Hristova, Iren Tzotcheva and Tsvetelina Velikova
Antibodies 2022, 11(2), 25; https://doi.org/10.3390/antib11020025
Available online: https://www.mdpi.com/2073-4468/11/2/25

5. “Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications”
by Guanjie Li, Hiroyuki Suzuki, Teizo Asano, Tomohiro Tanaka, Hiroyoshi Suzuki, Mika K. Kaneko and Yukinari Kato
Antibodies 2022, 11(2), 41; https://doi.org/10.3390/antib11020041
Available online: https://www.mdpi.com/2073-4468/11/2/41

6. “Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability”
by Dennis R. Goulet, Soumili Chatterjee, Wai-Ping Lee, Andrew B. Waight, Yi Zhu and Amanda Nga-Sze Mak
Antibodies 2022, 11(1), 6; https://doi.org/10.3390/antib11010006
Available online: https://www.mdpi.com/2073-4468/11/1/6

7. “Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents”
by Maxime Lecerf, Robin Lacombe, Alexia Kanyavuz and Jordan D. Dimitrov
Antibodies 2022, 11(1), 11; https://doi.org/10.3390/antib11010011
Available online: https://www.mdpi.com/2073-4468/11/1/11

8. “Antibody-Based Approaches to Target Pancreatic Tumours”
by Marie Sorbara, Pierre Cordelier and Nicolas Bery
Antibodies 2022, 11(3), 47; https://doi.org/10.3390/antib11030047
Available online: https://www.mdpi.com/2073-4468/11/3/47

9. “Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo”
by Jessica Bourque and Daniel Hawiger
Antibodies 2022, 11(1), 8; https://doi.org/10.3390/antib11010008
Available online: https://www.mdpi.com/2073-4468/11/1/8

10. “Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics”
by Taihei Murakami, Shigefumi Kumachi, Yasuhiro Matsunaga, Miwa Sato, Kanako Wakabayashi-Nakao, Hidekazu Masaki, Ryo Yonehara, Maiko Motohashi, Naoto Nemoto and Masayuki Tsuchiya
Antibodies 2022, 11(1), 10; https://doi.org/10.3390/antib11010010
Available online: https://www.mdpi.com/2073-4468/11/1/10

11. “Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope”
by Adva Mechaly, Eran Diamant, Ron Alcalay, Alon Ben David, Eyal Dor, Amram Torgeman, Ada Barnea, Meni Girshengorn, Lilach Levin, Eyal Epstein et al.
Antibodies 2022, 11(1), 21; https://doi.org/10.3390/antib11010021
Available online: https://www.mdpi.com/2073-4468/11/1/21

12. “Alternative Routes of Administration for Therapeutic Antibodies—State of the Art”
by Aubin Pitiot, Nathalie Heuzé-Vourc’h and Thomas Sécher
Antibodies 2022, 11(3), 56; https://doi.org/10.3390/antib11030056
Available online: https://www.mdpi.com/2073-4468/11/3/56

13. “Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors”
by Christopher W. Mount and Luis Nicolas Gonzalez Castro
Antibodies 2022, 11(2), 31; https://doi.org/10.3390/antib11020031
Available online: https://www.mdpi.com/2073-4468/11/2/31

14. “FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis”
by Margaret A. Lindorfer and Ronald P. Taylor
Antibodies 2022, 11(3), 45; https://doi.org/10.3390/antib11030045
Available online: https://www.mdpi.com/2073-4468/11/3/45

15. “Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions”
by Thomas Böldicke
Antibodies 2022, 11(3), 49; https://doi.org/10.3390/antib11030049
Available online: https://www.mdpi.com/2073-4468/11/3/49

16. “Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect”
by Toshihiko Tashima
Antibodies 2022, 11(4), 78; https://doi.org/10.3390/antib11040078
Available online: https://www.mdpi.com/2073-4468/11/4/78